NASDAQ | TSX: ACB
Canada's
leading medical cannabis provider and Australia's preeminent medical cannabis
supplier to bring three new premium strains to Australian
patients
EDMONTON, AB, Feb. 22,
2023 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:
ACB) (TSX: ACB), the Canadian company opening the world to
cannabis, and MedReleaf Australia today announced the launch of
CraftPlant, a new medical cannabis brand for patients in the
Australian market.
The CraftPlant brand includes three new products available for
doctors to prescribe – Greendae, Navana and HiVolt. All three are
developed from ultra-premium cultivars and are THC-dominant with
high percentages of terpenes. The cultivars were developed by Occo,
Aurora's leading science and genetics business. The new range is
produced under strict EU-GMP certified conditions and will be
available in 10g containers.
"Through our partnership with MedReleaf Australia, we are proud
to continue to lead the way in the Australian market with the
addition of new and innovative products for patients," says
Miguel Martin, CEO of Aurora
Cannabis. "As we build on our strategic international growth plans,
Australia has proven to be a very
promising and sustainable cannabis market that we are committed
to."
Aurora currently holds a 10% ownership stake in MedReleaf
Australia, a fully licensed, private company. Together, they
provide Australian patients with several Aurora-branded products,
including dried flower, oils and soft gels.
Russell Harding, CEO of MedReleaf
Australia says, "These new products are the result of dedicated
hard work by the teams in both Canada and Australia, providing the most unique cannabis
cultivars available in the Australian medical market. With
CraftPlant, doctors now have 27 MedReleaf products available for
their patients, providing a wide range of possible solutions for
patients unable to obtain relief from their prior medications or
treatment, and produced under the strictest guidelines."
For further information about CraftPlant, doctors and health
care professionals can contact MedReleaf's clinical support team or
visit their website: www.medreleafaustralia.com.au.
About Aurora
Aurora is opening the world to cannabis, serving both the
medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Whistler, Being and Greybeard, as well
as CBD brands, Reliva and KG7. Medical cannabis brands include
MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co.
Aurora also has a controlling interest in Bevo Farms Ltd.,
North America's leading supplier
of propagated agricultural plants. Driven by science and
innovation, and with a focus on high-quality cannabis products,
Aurora's brands continue to break through as industry leaders in
the medical, performance, wellness and adult recreational markets
wherever they are launched. Learn more at www.auroramj.com and
follow us on Twitter and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
About MedReleaf
Australia
MedReleaf Australia is a private company established in 2016.
MedReleaf is licensed by the Australian Federal Government's Office
of Drug Control (ODC) to cultivate and manufacture medical
cannabis. MedReleaf also has licences to import, export and
wholesale medical cannabis. Its wholly owned subsidiary, MedReleaf
NZ, also has a Medicinal Cannabis Supply Licence issued by the New
Zealand Ministry of Health.
MedReleaf Australia is backed by more than 50 years of
pharmaceutical and healthcare expertise, is driven by Research and
Development, and has an exclusive strategic partnership with
Canada's Aurora Cannabis
Enterprises.
An asset-lean distinct business positioned to take advantage of
a rapidly growing markets built to service the Australian and
New Zealand medical industries
including doctors, pharmacists, and patients.
Forward Looking
Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include, but are not limited to, statements
regarding the launch of new and innovative products to the
Australian market through partnership with MedReleaf Australia,
leadership in the Australian market through that partnership, and
strategic international growth plans, including a commitment to the
Australian market.
.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in
developing forward-looking statements include, without limitation,
publicly available information from governmental sources as well as
from market research and industry analysis and on assumptions based
on data and knowledge of this industry which the Company believes
to be reasonable. Forward-looking statements are subject to a
variety of risks, uncertainties and other factors that management
believes to be relevant and reasonable in the circumstances could
cause actual events, results, level of activity, performance,
prospects, opportunities or achievements to differ materially from
those projected in the forward-looking statements. These risks
include, but are not limited to, the ability to retain key
personnel, the ability to continue investing in infrastructure to
support growth, the ability to obtain financing on acceptable
terms, the continued quality of our products, customer experience
and retention, the development of third party government and
non-government consumer sales channels, management's
estimates of consumer demand in Canada and in jurisdictions where the Company
exports, expectations of future results and expenses, the risk of
successful integration of acquired business and operations,
management's estimation that SG&A will grow only in proportion
of revenue growth, the ability to expand and maintain distribution
capabilities, the impact of competition, the general impact of
financial market conditions, the yield from cannabis growing
operations, product demand, changes in prices of required
commodities, competition, and the possibility for changes in laws,
rules, and regulations in the industry, epidemics, pandemics or
other public health crises, including the current outbreak of
COVID-19, and other risks, uncertainties and factors set out under
the heading "Risk Factors" in the Company's annual information form
dated September 20, 2022 (the "AIF")
and filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com and filed
with and available on the SEC's website at www.sec.gov. The
Company cautions that the list of risks, uncertainties and other
factors described in the AIF is not exhaustive and other factors
could also adversely affect its results. Readers are urged to
consider the risks, uncertainties and assumptions carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on such information. The Company is under no
obligation, and expressly disclaims any intention or obligation, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
expressly required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-and-medreleaf-australia-launch-new-medical-cannabis-brand--craftplant-301752579.html
SOURCE Aurora Cannabis Inc.